成大生物：2025年净利润1.38亿元，同比下降59.86%

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the fiscal year 2025, primarily due to changes in the domestic rabies vaccine market and strategic adjustments in research and development [1] Group 1: Financial Performance - The company achieved total operating revenue of 1.39 billion yuan, a year-on-year decrease of 17.06% [1] - Net profit for the year was 138 million yuan, reflecting a year-on-year decline of 59.86% [1] Group 2: Factors Affecting Performance - Revenue decline was mainly influenced by changes in the domestic rabies vaccine market, including regulatory policy changes and intensified market competition, leading to reduced market demand [1] - The increase in asset impairment losses was primarily due to the company's strategic adjustment in R&D, resulting in the termination of the hib vaccine project and full impairment of capitalized R&D investments [1] - The increase in fair value gains was attributed to the recovery in asset valuations within the innovative drug sector of the private equity funds the company invested in [1] - The company experienced growth in overseas sales revenue and managed to mitigate some of the downward pressure on performance through effective control of sales and management expenses [1]